Table 5 Multivariate Cox proportional hazards models of survival among patients who received systemic anti-cancer treatment

 Female

1

1

 Male

1.56 (1.24–1.96)

1.38 (1.08–1.76)

  ≤ 49

1

1

 50–59

2.11 (1.14–3.89)

2.2 (1.18–4.08)

 60–69

1.80 (1.00–3.25)

1.87 (1.02–3.4)

 70–79

1.45 (0.80–2.64)

1.58 (0.86–2.92)

 80 ≥

1.67 (0.84–3.31)

1.93 (0.96–3.88)

 Diabetes

0.94 (0.71–1.26)

1.06 (0.78–1.43

 Cardiovascular

0.84 (1.05–1.43)

0.89 (0.69–1.14)

 Atrial fibrillation

1.00 (0.78–1.30)

0.99 (0.75–1.31)

 COPD

0.99 (0.80–1.25)

0.9 (0.71–1.13)

 Newly diagnosed

1.14 (0.88–1.47)

1.26 (0.96–1.65)

 Recurrence

1

1

 II

0.87 (0.21–3.52)

1.18 (0.28–4.98)

 III

1

1

 IV

0.96 (0.76–1.20)

1.11 (0.87–1.4)

 Adenocarcinoma

1

1

 Squamous

1.58 (1.21–2.06)

1.54 (1.15–2.08)

 SCLC

1.63 (1.19–2.24)

1.48 (1.07–2.05)

 Other

1.70 (1.29–2.24)

1.59 (1.18–2.14)

 Radiotherapy

1.02 (0.83–1.26)

0.9 (0.72–1.12)